Advertisement

Topics

Moderate-to-Severe Plaque Psoriasis - Biotech, Pharma and Life Science Channel

21:49 EDT 23rd June 2017 | BioPortfolio

Psoriasis is a chronic, immune disease that affects the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects up to 1.8 million people in the UK,ix approximately 20 percent of whom have moderate-to-severe plaque psoriasis.Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes and heart disease. The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.

News Articles [129 Associated News Articles listed on BioPortfolio]

Samsung Bioepis' Imraldi® (Adalimumab) Recommended for Approval by European Medicines Agency

The positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use will now be referred to the European Commission which will ...

LEO Pharma Appoints Chris Posner to Lead US Business

BALLERUP, Denmark, June 23, 2017 /PRNewswire/ -- LEO Pharma today announced that it appointed Chris Posner Executive Vice President Region US and President & CEO, LEO Pharma, Inc. From July 15...

Celebrated Photographer Martin Schoeller Shines a Light on People With Psoriatic Disease Including Olympic Swimmer and Author Dara Torres as Part of Celgene’s SHOW MORE OF YOU Campaign

Powerful, New Portraits Aim to Inspire People With Plaque Psoriasis or Psoriatic Arthritis to Show More of Their True Selves Award-winning portrait photographer Martin Schoell...

The Global Anti-Inflammatory Therapeutics Market Forecast 2017-2027

LONDON, June 22, 2017 /PRNewswire/ -- Revenue Prospects by Indication (Arthritis, Respiratory, MS, Psoriasis, IBD, Other), Drug Class (Corticosteroids, Anti-Inflammatory Biologics, NSAIDs, Other) ...

Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 Pipeline Review, H1 2017 [Updated: 20062017] Prices from

Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 P...

arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology

BREDA, The Netherlands and GHENT, Belgium, March 25, 2013 /PRNewswire/ -- ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation arGEN-X, a clinical stage biopharmaceutical co...

Novartis' Cosentyx and Eli Lilly's Taltz Bring Disruption to the Psoriasis Market as IL-17 Share Increases Dramatically

EXTON, Pa., June 21, 2017 /PRNewswire/ -- Spherix Global Insights recently released the results of an on-going, independent survey of US dermatologists (n=103) regarding evolving practice pattern...

Psoriasis Epidemiology Forecast To 2023 [Updated: 31052017] Prices from USD $2338

DelveInsight Psoriasis Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Psoriasis in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 1...

Plaque Psoriasis Psoriasis VulgarisAPI Insights, 2017 [Updated: 30052017] Prices from USD $1063

The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of b...

National Psoriasis Foundation awards University of Pennsylvania medical resident its inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship

PORTLAND, Ore., July 2, 2013 /PRNewswire-USNewswire/ -- The National Psoriasis Foundation awarded Zelma Chiesa Fuxench, M.D., of the University of Pennsylvania, its inaugural Dr. Mark G. Lebwohl ...

Events [0 Results]

None

Companies [20 Associated Companies listed on BioPortfolio]

Tiziana Life Sciences plc

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The C...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and a...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, ...

Akaal Pharma Pty Ltd.

Akaal Pharma Pty Ltd (Akaal Pharma) is a clinical-stage drug discovery and development company focused on the development of novel small molecule drugs for the treatment of inflam...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and p...

Helmedix Pty Ltd

Helmedix is developing new therapies for autoimmune diseases. The company has identified peptides derived from helminthic worms that have immune-modulating properties. These peptides are being explo...

HealOr

Founded in 2002, HealOr is a privately owned, clinical-stage specialty biopharmaceutical company developing a first-in-class pipeline of topical therapeutics to treat a variety of...

fOCUS Pharmaceuticals, LLC

fOCUS Pharmaceuticals is a privately held generic and branded pharmaceutical company specializing in the research and development of prescription dermatology products. Our primary focus are in the are...

Lycera Corp.

Lycera Corp. is focused on the discovery and development of small-molecule immunomodulators for the treatment of immunologic diseases, including psoriasis, rheumatoid arthritis, lupus erythematosis, i...

Clinical Trials [534 Associated Clinical Trials listed on BioPortfolio]

Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis

This study aims to evaluate more objectively, through an imaging technique such as ultrasound, changes in joints and entheses of patients with active psoriatic arthritis (PAs) who will sta...

Evaluation of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis

This is a proof of concept, investigator blinded study to evaluate the efficacy and safety of a novel combination of a home narrow band ultraviolet B (NBUVB) lamp with an occlusive dressin...

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

The purpose of this study is to evaluate the potential of DFD-06 to suppress the hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days.

A Study of KY1005 in Healthy Volunteers and Volunteers With Psoriasis

This is a single and multiple ascending dose, placebo-controlled, double-blind, Phase 1 study to evaluate the safety and tolerability of KY1005 in healthy volunteers and volunteers with mi...

Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients

To identify possible genetic associations of clinical response to anti-IL-17A (Secukinumab) treatment in psoriasis using a combined gene association study and gene expression analysis. To...

Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients

This study aims to identify and describe the presence of itch active molecules in psoriasis and response to treatment with apremilast. This data will be complemented by immunohistochemical...

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

This is a study to assess the pharmacokinetics, safety and tolerability of multiple ascending oral doses of ABBV-553 in healthy volunteers and the pharmacokinetics, safety, tolerability an...

The DIET Trial - Dietetic Intervention in Psoriatic Arthritis

Psoriasis (Ps) and psoriatic arthritis (PsA) are associated with increased risk of metabolic syndrome (MetS), body fatness and cardiovascular risk. Additionally, oxidative stress and infla...

Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.

Safety and Efficacy of Secukinumab in Mild Psoriasis

Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities. By curing mil...

PubMed Articles [350 Associated PubMed Articles listed on BioPortfolio]

Withasteroid B from D. metel L. Regulates Immune Responses by Modulating the JAK/STAT Pathway and the IL-17(+) RORγt(+) /IL-10(+) FoxP3(+) Ratio.

Datura metel L. is a medicinal herb that contains withasteroids and has a wide range of biological activities. We isolated 7 withasteroids from the flowers of D. metel L(1) . and examined their abilit...

Patch testing in psoriasis patients: results of a 30-year retrospective study.

Psoriasis and allergic contact dermatitis (ACD) are common, chronic T-lymphocyte mediated conditions. Although psoriasis patients are commonly referred for patch testing, there are conflicting views o...

The association between 38 previously reported polymorphisms and psoriasis in a Polish population: High predicative accuracy of a genetic risk score combining 16 loci.

To confirm the association of previously discovered psoriasis (Ps) risk loci with the disease in a Polish population and to create predictive models based on the combination of these single nucleotide...

An Anchoring-Based Intervention to Increase Patient Willingness to Use Injectable Medication in Psoriasis.

Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease.

Psoriasis, psoriatic arthritis (PsA), and inflammatory bowel disease (IBD) are related inflammatory immune-mediated diseases, with considerable overlap. However, it is as yet unclear whether co-occurr...

Factors associated with the choice of the first biologic in psoriasis: Real life analysis from the Psobioteq cohort.

Decision making is a complex process. The aim of our study was to assess factors associated with the choice of the first biological treatment in patients with moderate-to-severe psoriasis.

Psoriasis Comorbidity affects Multiple Sclerosis Neurological Progression: a retrospective case -control analysis.

Multiple sclerosis (MS) and psoriasis are inflammatory disorders, with epidemiological and biological associations. The impact of one disease on the course of the other has not been studied.

The efficacy of short term clobetasol lotion in the treatment of scalp psoriasis.

Scalp psoriasis can have a considerable impact on patients' quality of life and is considered difficult to treat. Treatment failure may, however, be due to poor adherence, as application of topical tr...

Musculoskeletal disease in MDA5-related type I interferonopathy - a Mendelian mimic of Jaccoud's arthropathy.

Objectives To define the molecular basis of a multisystem phenotype with progressive musculoskeletal disease of the hands and feet including camptodactyly, subluxation and tendon rupture reminiscent o...

Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa.

Hidradenitis suppurativa (HS) is a recalcitrant chronic skin disease with poorly understood immunopathogenic mechanisms. Previous studies reported that the interleukin-36 (IL-36) cytokines (IL-36α, I...

Videos

None available.

Medical and Biotech [MESH] Definitions

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Quick Search
Advertisement
 

Relevant Topics

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

review and buy Moderate-to-Severe Plaque Psoriasis market research data and corporate reports here

Channels Quicklinks